3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
15
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Liposarcoma
2
Glioma
2
Carcinoma, Renal Cell
2
von Hippel-Lindau Disease
1
Xanthogranuloma, Juvenile
1
Wilms Tumor
1
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Interventions
Fulvestrant
2
tivozanib
1
ribociclib
1
palbociclib
1
niraparib
1
lorlatinib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Tamoxifen
1
STX-478
1
Metformin
1
Letrozole
1
Imlunestrant
1
Cetuximab
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
palbociclib
×
30 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled